Fit For Purpose: Antiretroviral Treatment Optimization
July 2015 By Polly Clayden The most striking news since the 2014 Pipeline Report is from the START (Strategic Timing of AntiRetroviral Treatment) study.1 We now have evidence from a large, randomized, controlled trial to show that CD4 count is…